Immunic (IMUX) Accounts Payables (2013 - 2026)

Immunic (IMUX) has 14 years of Accounts Payables data on file, last reported at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 83.18% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (up 83.18% YoY), and the FY2025 full-year result was $10.1 million, up 29.21% from the prior year.
• Accounts Payables rose to $11.0 million in Q1 2026, from $10.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $11.0 million in Q1 2026 to a low of $3.2 million in Q3 2023.
• A 5-year average of $6.2 million and a median of $6.0 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 67.28% in 2022 and surged 88.87% in 2024, its largest moves.
• Tracing IMUX's Accounts Payables over 5 years: stood at $4.3 million in 2022, then advanced by 19.11% to $5.1 million in 2023, then soared by 53.87% to $7.8 million in 2024, then grew by 29.21% to $10.1 million in 2025, then rose by 8.61% to $11.0 million in 2026.
• Business Quant data shows IMUX's Accounts Payables at $11.0 million in Q1 2026, $10.1 million in Q4 2025, and $7.9 million in Q3 2025.